Περίληψη:
Treatment with recombinant human erythropoietin (rHuEpo) improves
anaemia in approximately 20% of patients with myelodysplastic syndromes
(MDS). We investigated the potential advantage of a prolonged
administration of rHuEpo to achieve higher erythroid response rates (RR)
in 281 MDS patients: 118 with refractory anaemia (RA), 77 with
refractory anaemia and ringed sideroblasts (RARS), 59 with refractory
anaemia with excess of blasts and blast count < 10% (RAEB-I), and 27
with RAEB and blast count between 11-20% (RAEB-II). rHuEpo was given
subcutaneously at a dose of 150 U/kg thrice weekly, for a minimum of 26
weeks. Response to treatment was evaluated after 12 and 26 weeks of
therapy. The overall RR was 45.1%; the RR for RA, RARS, RAEB-I and
RAEB-II were 48.3%, 58.4%, 33.8% and 13% respectively. A significant
increase in RR was observed at week 26 in RA, RARS and RAEB-I patients,
as the response probability increased with treatment duration. The RR
was higher in the good cytogenetic prognostic group and serum Epo level
of > 150 U/l at baseline predicted for non-response. The median duration
of response was 68 weeks and the overall risk of leukaemic
transformation was 21.7%. These results suggest that prolonged
administration of rHuEpo produces high and long-lasting erythroid RR in
MDS patients with low blast counts, particularly in those with
pretreatment serum Epo levels of < 150 U/l and good cytogenetic
prognosis.
Συγγραφείς:
Terpos, E
Mougiou, A
Kouraklis, A
Chatzivassili, A and
Michalis, E
Giannakoulas, N
Manioudaki, E
Lazaridou, A and
Bakaloudi, V
Protopappa, M
Liapi, D
Grouzi, E and
Parharidou, A
Symeonidis, A
Kokkini, G
Laoutaris, NP and
Vaipoulos, G
Anagnostopoulos, NI
Christakis, JI
Meletis, J
and Bourantas, KL
Zoumbos, NC
Yataganas, X
Viniou, NA and
Greek MDS Study Grp
